Cybin Inc (HELP)

Cybin Inc., which does business as Helus Pharma, is a clinical-stage neuropsychiatry company focused on developing psychedelic-based therapeutics for people with mental health conditions. The company’s pipeline includes CYB003, a deuterated psilocybin analog being evaluated in a phase 3 trial for major depressive disorder, and CYB004, a deuterated N, N-dimethyltryptamine (DMT) program in phase 2 testing for generalized anxiety disorders. Its additional programs include SPL028, an injectable deuterated DMT that has completed phase 1 intramuscular and intravenous clinical studies, SPL026 for major depressive disorder, and CYB005, a phenethylamine derivative in preclinical development for central nervous system disorders. Cybin also maintains a broader research pipeline of investigational psychedelic-based compounds and has a strategic partnership with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program for CYB003 in adjunctive major depressive disorder. The company is headquartered in Toronto, Canada.

Jump directly to the stock analysis sections supported by the latest available data.